Atea Pharmaceuticals (AVIR) Equity Ratio (2019 - 2026)
Atea Pharmaceuticals' Equity Ratio history spans 8 years, with the latest figure at 0.88 for Q1 2026.
- Quarterly Equity Ratio fell 6.35% to 0.88 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.88 through Mar 2026, down 6.35% year-over-year, with the annual reading at 0.87 for FY2025, 7.48% down from the prior year.
- Equity Ratio came in at 0.88 for Q1 2026, roughly flat from 0.87 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.97 in Q1 2023 to a low of 0.87 in Q4 2025.
- The 5-year median for Equity Ratio is 0.93 (2025), against an average of 0.94.
- Year-over-year, Equity Ratio soared 40.13% in 2022 and then dropped 7.48% in 2025.
- Atea Pharmaceuticals' Equity Ratio stood at 0.96 in 2022, then dropped by 2.88% to 0.93 in 2023, then rose by 1.21% to 0.94 in 2024, then fell by 7.48% to 0.87 in 2025, then increased by 0.15% to 0.88 in 2026.
- Per Business Quant, the three most recent readings for AVIR's Equity Ratio are 0.88 (Q1 2026), 0.87 (Q4 2025), and 0.92 (Q3 2025).